Evaluating the Impact of -11.01 Increase on Ocuphire Pharma Inc’s (OCUP) Stock

The stock of Ocuphire Pharma Inc (OCUP) has gone down by -4.43% for the week, with a -21.46% drop in the past month and a -36.81% drop in the past quarter. The volatility ratio for the week is 8.69%, and the volatility levels for the past 30 days are 7.38% for OCUP. The simple moving average for the past 20 days is -6.87% for OCUP’s stock, with a -39.57% simple moving average for the past 200 days.

Is It Worth Investing in Ocuphire Pharma Inc (NASDAQ: OCUP) Right Now?

Moreover, the 36-month beta value for OCUP is 0.32. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for OCUP is 22.89M and currently, short sellers hold a 7.20% of that float. On April 04, 2024, OCUP’s average trading volume was 213.59K shares.

OCUP) stock’s latest price update

Ocuphire Pharma Inc (NASDAQ: OCUP) has experienced a decline in its stock price by -11.01 compared to its previous closing price of 2.18. However, the company has seen a fall of -4.43% in its stock price over the last five trading days. InvestorPlace reported 2024-02-26 that While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

OCUP Trading at -19.10% from the 50-Day Moving Average

After a stumble in the market that brought OCUP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.61% of loss for the given period.

Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 8.69%, as shares sank -20.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.45% lower at present.

During the last 5 trading sessions, OCUP fell by -4.43%, which changed the moving average for the period of 200-days by -51.38% in comparison to the 20-day moving average, which settled at $2.06. In addition, Ocuphire Pharma Inc saw -35.55% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at OCUP starting from Jhaveri Nirav S., who purchase 10,000 shares at the price of $2.10 back on Mar 21 ’24. After this action, Jhaveri Nirav S. now owns 150,000 shares of Ocuphire Pharma Inc, valued at $21,000 using the latest closing price.

SCHACHLE JOSEPH K, the Chief Operating Officer of Ocuphire Pharma Inc, purchase 2,000 shares at $2.05 during a trade that took place back on Mar 21 ’24, which means that SCHACHLE JOSEPH K is holding 2,000 shares at $4,100 based on the most recent closing price.

Stock Fundamentals for OCUP

Current profitability levels for the company are sitting at:

  • -0.55 for the present operating margin
  • 1.0 for the gross margin

The net margin for Ocuphire Pharma Inc stands at -0.51. The total capital return value is set at -0.21. Equity return is now at value -20.77, with -19.40 for asset returns.

Currently, EBITDA for the company is -10.56 million with net debt to EBITDA at 5.16. When we switch over and look at the enterprise to sales, we see a ratio of -0.12. The receivables turnover for the company is 8.17for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.35.


To wrap up, the performance of Ocuphire Pharma Inc (OCUP) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts